A 74-year-old man who developed systemic contact dermatitis due to intravesical chemotherapy with mitomycin C (mC) is herein described. The rash developed about 2 days after the third intravesical instillation of mC for superficial bladder carcinoma. It was characterized by diffuse erythematous and scaling patches, mainly located at the folds. Treatment with 25 mg/day of prednisone and the suspension of mC treatment led to the clearing of the rash. Patch test with the drug 10% in water and ROAT with the drug as is were positive. MC is an alkylating agent used by intravesical instillation to treat bladder carcinoma. Reports suggest that up to 9% of the treated patients develop skin reactions, systemic allergic contact dermatitis being one of the commonest. Systemic contact dermatitis is a not always simple diagnosis due to the aspecific clinical features and to the difficulties in patch testing with mC.
Systemic allergic contact dermatitis due to mitomycin C: A case report
Patruno C.;
2010-01-01
Abstract
A 74-year-old man who developed systemic contact dermatitis due to intravesical chemotherapy with mitomycin C (mC) is herein described. The rash developed about 2 days after the third intravesical instillation of mC for superficial bladder carcinoma. It was characterized by diffuse erythematous and scaling patches, mainly located at the folds. Treatment with 25 mg/day of prednisone and the suspension of mC treatment led to the clearing of the rash. Patch test with the drug 10% in water and ROAT with the drug as is were positive. MC is an alkylating agent used by intravesical instillation to treat bladder carcinoma. Reports suggest that up to 9% of the treated patients develop skin reactions, systemic allergic contact dermatitis being one of the commonest. Systemic contact dermatitis is a not always simple diagnosis due to the aspecific clinical features and to the difficulties in patch testing with mC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
